Lincoln Pharmaceuticals delivered robust financial performance for FY26, with consolidated total income reaching ₹704.5 crore, representing a growth of 9.1% from ₹645.7 crore in FY25. The company's net profit increased 6.7% to ₹87.9 crore from ₹82.3 crore in the previous year, while EBITDA rose 5.8% to ₹131.1 crore. The board recommended a final dividend of ₹1.80 per share for FY26, representing an 18% dividend payout on equity shares with a face value of ₹10 each. For Q4FY26, the company reported a consolidated net profit of ₹11.6 crore, compared to ₹11.57 crore in Q4FY25, registering a marginal growth of 0.52% year-on-year. Revenue from operations for the quarter stood at ₹187.3 crore, compared to ₹166.3 crore in Q3FY26, reflecting a growth of 13% sequentially.
EBITDA for Q4FY26 came in at ₹20.66 crore, compared to ₹19.84 crore in Q4FY25, marking a growth of 4.13% YoY. Earnings per share (EPS) for the quarter stood at ₹5.81, compared to ₹14.28 in Q3FY26. The company's financial performance during the quarter was impacted by war-related developments and the global business environment. Total expenses during Q4FY26 increased to ₹166.4 crore compared to ₹146.7 crore in Q3FY26, mainly due to higher raw material consumption and employee expenses. Finance costs remained low at ₹0.3 crore during the quarter. For the full financial year FY26, the company reported revenue growth driven by strong domestic and export market demand, while profitability remained stable amid rising operational and input costs.
During FY26, Lincoln Pharmaceuticals received significant regulatory approvals to support its global expansion strategy. The company received approvals from TGA Australia and EU GMP for further global expansion. Currently, the company exports to more than 60 countries and plans to expand its presence to 90 countries over the next two to three years. The company remains focused on expanding into regulated and semi-regulated international markets, with growth supported by demand across cardiac, diabetic, dermatology and ENT segments. Lincoln Pharmaceuticals is targeting revenue of ₹1,000 crore within the next three years through expansion into new markets and higher-value products, supported by its debt-free balance sheet.
CRISIL Ratings reaffirmed its 'CRISIL A/Stable/CRISIL A1' ratings on Lincoln Pharmaceuticals' bank facilities on January 9, reflecting the promoters' strong industry experience, established market position, and healthy financial profile. The company remains committed to expanding its global footprint while addressing diverse healthcare needs, with the rating reaffirmation despite working capital intensity and regulatory and competitive challenges.
